Periostin has been detected in a wide variety of normal tissues, and especially in tissues under stress conditions such as heart under pressure or volume overload and skeletal muscle after injury. Periostin (POSTN), also referred to as osteoblast-specific factor 2, is a 93.3-kDa extracellular matrix (ECM) protein that was identified in murine osteoblast-like cells in 1993. Therefore, new biomarkers for prognosis of NSCLC are needed. However, due to their low sensitivity and specificity, these biomarkers have limited ability to predict the prognosis of NSCLC.
Several serum-based tumor biomarkers have been applied to monitor cancer treatment, such as neuron-specific enolase (NSE), cytokeratin 19 fragment (CYFRA21-1), and carcinoembryonic antigen (CEA). Despite the promising development of molecular-targeted therapies, the outcomes of patients with stage III/IV NSCLC remains unsatisfactory, with a 5-year survival rate around 16%. Routine treatments for NSCLC include surgery, chemotherapy, and radiotherapy, but the benefits of these treatments are limited for patients in advanced stages. NSCLC is the most common type of lung cancer, and accounts for 80–90% of all the lung cancer cases. In 2018, over 230 000 new cases of lung cancer (13% of all cancer diagnoses) and over 150 000 deaths (25% of cancer deaths) were reported in the United States. Lung cancer is the leading cause of cancer-associated mortality globally in both men and women. Keywords: non-small cell lung cancer, Prognosis, Periostin, meta-analysis Periostin may serve as a prognostic biomarker for NSCLC patients. Subgroup analyses were performed based on different issues, such as districts, antibodies and methods for periostin detection.ĬONCLUSIONS: Overexpression of periostin is a negative prognostic factor and is associated with worse overall survival (OS) in NSCLC patients. Heterogeneity was significant among the studies, but publication bias was lacking. RESULTS: This meta-analysis enrolled 2504 NSCLC cases from 12 eligible studies. Sensitivity and subgroup analyses and assessment of publication bias were also conducted. Pooled hazard ratios (HR) with 95% confidence interval (CI) were calculated using the random-effects model.
Eligible studies reported at least 1 of the following clinical outcome measures: overall survival, progression-free survival, cancer-specific survival, relapse-free survival, disease-free survival, or other clinical parameters of prognosis. Published and unpublished studies investigating the correlation between periostin expression and the prognosis of NSCLC were included in this meta-analysis. MATERIAL AND METHODS: A meta-analysis was performed on data acquired from PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang Database from inception to 18 June 2022. This meta-analysis evaluated the correlation between periostin expression and the prognosis of NSCLC. However, the research results were inconsistent. Periostin was found to be associated with the prognosis of NSCLC. BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related death in the world and its poor prognosis is a major concern.
0 kommentar(er)
